Oral Weight-Loss Pill Orforglipron: Ozempic 2.0
Eli Lilly's daily pill orforglipron shows 12% weight loss in trials, potentially revolutionizing obesity treatment. Could this be the end of injections?
Eli Lilly's daily pill orforglipron shows 12% weight loss in trials, potentially revolutionizing obesity treatment. Could this be the end of injections?
Leading bariatric specialists Dr. Todkar, Dr. Dukkipati & Dr. Garg share crucial insights on managing India's dual health crisis through early intervention & lifestyle changes. Act now for better health!
Childhood obesity in India surges from 3-4% to 8-9%, driven by lifestyle changes and mental health factors. Dr. Atul Peters reveals how families can reverse this alarming trend through simple changes.
India's pharmaceutical industry is transitioning toward innovative drugs, with multiple companies preparing obesity reduction launches. Discover how PHARMEXCIL is driving this competitive transformation.
A new report reveals a sharp 5-fold increase in obesity in India over 30 years, affecting 1 in 4 adults. Learn about the health risks and what it means for the nation.
New Lancet study reveals 25% of Indians face obesity, costing economy ₹29,000 crore annually. Urgent public health action needed to address this growing crisis.
New OSSI survey reveals insurance barriers prevent timely obesity treatment in India. Learn how policy gaps affect patient care and what needs to change.
PGI Chandigarh warns of a sharp increase in Type 2 diabetes among children and young adults, driven by junk food and sedentary lifestyles. Learn how to prevent it.
Lancet study reveals India's ultra-processed food epidemic with retail sales skyrocketing 40-fold since 2006, driving obesity and diabetes crisis among youth. Experts demand urgent policy reforms.
Discover the top 6 lifestyle diseases affecting Indians, their causes, symptoms, and preventive measures. Learn how to protect your health today!
Novo Nordisk reduces Wegovy's price to $349 and prepares an aggressive launch for its oral weight-loss pill to combat competition from Eli Lilly and expand patient access.
Lars Rebien Sorensen returns as Novo Nordisk chairman after board shakeup. The move follows Pfizer's $10B Metsera acquisition, intensifying obesity drug competition.
Assam Police reports significant fitness improvement with only 2.06% of 73,317 personnel classified as obese in annual BMI tests. Discover how the force is getting leaner and mission-ready.
A 16-year-old Mumbai student reversed his Type 2 diabetes risk factors. Discover how an endocrinologist's plan involving diet, exercise, and family support led to a 7 kg weight loss and improved HbA1c levels in six months.
Arjun Kapoor speaks candidly about his mental health journey, starting therapy during lockdown, and overcoming obesity. Read his powerful message on strength.
A 36-year-old Chinese man died days after gastric bypass surgery he hoped would help him impress his girlfriend's parents. The tragedy sparks debate about weight-loss surgery risks.
Lancet study shows child hypertension doubled 2000-2020. 114 million affected globally. Obesity, poor diet, sedentary lifestyles identified as key triggers. Learn prevention strategies.
Novo Nordisk reduces Wegovy price by 37% in India, intensifying the weight loss drug war with Eli Lilly's Mounjaro. Discover the new costs and market impact.
Novo Nordisk reduces its weight loss drug Wegovy's price by 37% in India, intensifying competition with Eli Lilly's Mounjaro. Get the latest details on the new pricing and market dynamics.
Trump administration secures obesity drug price cuts with Eli Lilly and Novo Nordisk. Medicare coverage expansion opens 30 million patient market starting April 2026. Read analysis.
Discover the surprising reasons why Indian markets are struggling to reach new peaks despite robust economic growth and controlled inflation. Expert analysis reveals the hidden factors holding back the bull run.
In a major victory for American patients, pharmaceutical titans Eli Lilly and Novo Nordisk announce significant price reductions for popular weight-loss medications after Trump's intervention.
Medical experts warn of alarming surge in obesity and heart attacks among young Indians. Discover how adopting Blue Zone lifestyle principles could reverse this dangerous trend.
Discover why revolutionary weight-loss drugs aren't magic bullets for India's obesity crisis. Learn about limitations, costs, and sustainable solutions.
New data exposes America's weight divide: Discover which states top the obesity charts and which maintain healthier lifestyles in this comprehensive health analysis.
Former US President Donald Trump is negotiating with Novo Nordisk to offer weight-loss drugs at just $149. Discover how this could revolutionize affordable healthcare and impact India's growing obesity crisis.
Indian stock markets witnessed massive selling pressure as Sensex crashed 500 points and Nifty ended below 25,600. Discover the 10 major factors behind today's market meltdown and what it means for investors.
Foreign portfolio investors unleash massive capital into India's booming primary market as IPO frenzy hits new highs. Discover what's driving this unprecedented inflow and whether the rally can sustain.
Discover how one woman transformed her life by losing 70kg without relying on willpower alone. Her surprising revelation about what really causes weight gain will change everything you thought you knew about dieting.
Breaking news: US FDA approves Rybelsus, the groundbreaking oral weight loss medication that mimics popular injection drugs. Discover how this pill could revolutionise obesity treatment in India and worldwide.